PERKINELMER PROVIDES COMPREHENSIVE SOLUTIONS FOR COLLABORATION ON NIH ROADMAP INITIATIVE

PerkinElmer Inc. (NYSE: PKI), a global leader in Health Sciences and Photonics, today announced that it has entered a collaborative agreement with the National Institute of Health’s National Chemical Genomics Center (NCGC) to provide reagents, instrumentation and scientific support for identifying small molecules, which can be valuable tools for understanding important cellular events involved in health and disease, potentially leading to drug discovery.

As part of the collaboration, NCGC gains access to PerkinElmer’s extensive reagent portfolio and scientific experts who are helping develop assays and protocols. The three leading reagent technologies being used are AlphaScreen™, LANCE™ and DELFIA™. AlphaScreen is an extremely sensitive non-radioactive homogeneous bead-based technology that allows the screening of a wide range of biological interactions, particularly with the largest target class – kinases. LANCE is a robust homogeneous technology that supports the measurement of various analytes and screens diverse biological interactions. DELFIA, the heterogeneous counterpart to LANCE, is an enabling time-resolved fluorescence technology allowing for sensitive and multiplexed detection of analytes.

“We are very pleased to be partnering with NCGC to help accelerate their chemical genomics efforts,” said Robert F. Friel, president, PerkinElmer Life and Analytical Sciences. “We believe that our capability to provide comprehensive solutions helps eliminate the time consuming and expensive problem of trying to unify all the components of drug discovery – liquid handling and prep, assay development and multilabel detection.”